EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission

Kaviyon Sadrolashrafi, Wolfram Samlowski iD

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Kaviyon Sadrolashrafi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Checkpoint blockade has improved the response rate and survival in metastatic melanoma. Elective treatment discontinuation appears to be reasonable in most patients who have achieved a confirmed complete remission. It seems crucial to understand whether restarting immune checkpoint inhibitor therapy can induce additional responses or remissions in rare patients who relapse.

Methods

A retrospective analysis identified only 10 patients who relapsed after elective treatment discontinuation after a radiologically confirmed remission. These patients were retreated with single-agent PD-1 or combined CTLA-4 plus PD-1-directed monoclonal antibodies.

Results

We found an initial complete response rate of 20% (2 patients) following retreatment. With a median follow-up of 26 months, the addition of individualized salvage therapies converted an additional 4 patients to a 2nd remission. All 6 of these patients have again discontinued therapy. Three patients have died of metastatic melanoma, while another is receiving salvage therapy. Six of our 10 patients experienced grades 2-3 retreatment-related toxicity. There were no hospitalizations or fatalities.

Discussion

Retreatment of relapsing patients resulted in 20% complete responses with checkpoint inhibitors. The planned addition of other treatment modalities converted another 4 patients (40%) to a durable 2nd remission. This sequential approach merits further exploration in prospective clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansRetrospective StudiesProspective StudiesProgrammed Cell Death 1 ReceptorNeoplasm Recurrence, LocalRetreatmentIpilimumabCutaneous Malignant Melanoma

Stichwörter der Autor:innen

ipilimumabnivolumabpembrolizumabstereotactic ablative radiotherapytargeted therapy

Substanzen

Programmed Cell Death 1 ReceptorIpilimumab

Autor:innen und Institutionen

  • Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, USA.
  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.
  • University of Nevada School of Medicine, Reno, NV, USA.

ORCID-Profile: Wolfram Samlowski

Zitieren

APA

Sadrolashrafi, K., & Samlowski, W. (2023). Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission. The Oncologist. https://doi.org/10.1093/oncolo/oyad016

Vancouver

Sadrolashrafi K, Samlowski W. Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission. The Oncologist. 2023. doi:10.1093/oncolo/oyad016

BibTeX
@article{Sadrolashrafi2023,
  author = {Sadrolashrafi, Kaviyon and Samlowski, Wolfram},
  title = {Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad016}
}
Kostenlos starten →